The rise of Sildenafil initially fueled a boom for major pharmaceutical companies, however recent changes present a murky outlook for shareholders. Generic alternatives are eroding earnings, and ongoing patent https://umarzolf160386.elbloglibre.com/41557238/the-blue-pill-and-pharma-a-volatile-bet